Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini(Cleveland Clinic), Bernard Escudier(Institut Gustave Roussy), Piotr Tomczak(Poznan University of Medical Sciences), А. Д. Каприн(Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology), Cezary Szczylik(Central Clinical Hospital), Thomas E. Hutson(Texas Oncology), M. Dror Michaelson(Massachusetts General Hospital), В. А. Горбунова, Martin Gore(Royal Marsden Hospital), И. Г. Русаков(P.A. Hertzen Moscow Oncology Research Institute), Sylvie Négrier(Centre Léon Bérard), Yen-Chuan Ou(Taichung Veterans General Hospital), Daniel Castellano(Hospital Universitario 12 De Octubre), Ho Yeong Lim(Samsung Medical Center), Hirotsugu Uemura(Kindai University Hospital), Jamal Tarazi(Pfizer (United States)), David Cella(Northwestern University), Connie Chen(Pfizer (United States)), Brad Rosbrook(Pfizer (United States)), Sinil Kim(Pfizer (United States)), Robert J. Motzer(Memorial Sloan Kettering Cancer Center)
Cited by 1,842
Abstract
Related Papers
No related papers found
Powered by citation graph analysis